SCHEMBL4286543

SCHEMBL4286543

CC(C)(C)OC(=O)Nc1ccc(C(=O)Nc2nccs2)cc1

nearest known ligand 0.74

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
AGER Q15109 1/20 0.68
ADORA2A P29274 8/20 0.64
METAP1 P53582 1/20 0.63
RAB9A P51151 7/20 0.61
NPC1 O15118 6/20 0.61
SMN1; SMN2 Q16637 3/20 0.61
CYP2C19 P33261 2/20 0.61
CYP2C9 P11712 1/20 0.59
CYP3A4 P08684 1/20 0.59
HSD17B10 Q99714 2/20 0.58
NAMPT P43490 1/20 0.58
MEN1 O00255 1/20 0.58
KMT2A Q03164 1/20 0.58
LMNA P02545 1/20 0.58
RECQL P46063 1/20 0.58
L3MBTL1 Q9Y468 1/20 0.58
MAPT P10636 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5493836 0.84 AGER (0.64) AGERADORA2ARAB9ANPC1SMN1; SMN2
SCHEMBL14720 0.84 METAP1 (0.66) ADORA2AMETAP1RAB9ANPC1SMN1; SMN2
SCHEMBL8298569 0.83 AGER (0.73) AGERADORA2ARAB9ANPC1SMN1; SMN2
SCHEMBL16603980 0.81 AGER (1.00) AGERADORA2ARAB9ANPC1SMN1; SMN2
SCHEMBL4296490 0.81 AGER (0.70) AGERADORA2ARAB9ANPC1SMN1; SMN2
SCHEMBL21661749 0.81 NAMPT (0.72) RAB9ANPC1SMN1; SMN2NAMPTMEN1
SCHEMBL1091450 0.81 NAMPT (0.52) AGERMETAP1NAMPT
SCHEMBL3194666 0.80 ADORA2A (0.75) AGERADORA2ARAB9ANPC1SMN1; SMN2
SCHEMBL4286447 0.80 RAB9A (0.65) AGERADORA2ARAB9ANPC1SMN1; SMN2
SCHEMBL5502572 0.80 AGER (0.76) AGERADORA2ARAB9ANPC1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090247593-A1 N-THIAZOL-2-YL-BENZAMIDE DERIVATIVES H. LUNDBECK A/S (DK) 2009-10-01 US disclosed
EP-1803455-A1 N-thiazol-2-yl-benzamide derivatives H.Lundbeck A/S (DK) 2007-07-04 EP disclosed
EP-1682129-B1 N-THIAZOL-2-YL-BENZAMIDE DERIVATIVES LUNDBECK & CO AS H (DK) 2007-02-21 EP disclosed
EP-1682129-A1 N-THIAZOL-2-YL-BENZAMIDE DERIVATIVES H. LUNDBECK A/S (DK) 2006-07-26 EP disclosed
US-20060154974-A1 N-thiazol-2-yl-benzamide derivatives H. LUNDBECK A/S (DK) 2006-07-13 US disclosed
WO-2005039572-A1 N-THIAZOL-2-YL-BENZAMIDE DERIVATIVES H. LUNDBECK A/S (DK) 2005-05-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090247593-A1 N-THIAZOL-2-YL-BENZAMIDE DERIVATIVES ADORA2A, ADORA3, ADORA1 AGER 824/4885ADORA2A 1/4885METAP1 2028/4885
US-20060154974-A1 N-thiazol-2-yl-benzamide derivatives ADORA2A, ADORA3, ADORA1 AGER 824/4885ADORA2A 1/4885METAP1 2028/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.